If you would like to request to license this or any other OncoLink content for your corporate or educational purposes, please contact our Director of Strategic Partnerships for pricing
Maggie Hampshire RN, BSN, OCN
Director of Strategic Partnerships
3400 Civic Center Boulevard, Suite 2338
Philadelphia, PA 19104
Dec 22, 2014 - Long-term survival may be increased in medium-risk prostate cancer patients who receive short-term androgen deprivation therapy before and during radiation treatment compared with men who receive radiation alone. In addition, proton beam therapy may be associated with a decreased risk of disease recurrence after 10 years and has minimal side effects after one year, according to research presented at the 51st Annual Meeting of the American Society for Radiation Oncology, held from Nov. 1 to 5 in Chicago.
Apr 18, 2012
Dec 22, 2014